Soluble CD40L in peripheral artery disease

Summary

Although soluble CD40L (sCD40L, possibly derived from platelets and pro-inflammatory in vitro) may be implicated in thrombosis and haemostasis, there are little data in peripheral artery disease (PAD). We hypothesised the following: (a) that sCD40L relates to the clinical severity of PAD; and (b) that peripheral artery angioplasty acutely raises sCD40L levels. sCD40L was compared to established platelet markers soluble P selectin, platelet microparticles and platelet surface expression of CD62 and CD63. We recruited 36 healthy controls, 33 patients with intermittent claudication (IC), and 33 with symptomatically more severe critical limb is chaemia (CLI), measuring plasma markers by ELISA and membrane markers by flow cytometry. Eleven patients with CLI subsequently underwent peripheral artery angioplasty: blood was taken before and 10 minutes after the intervention. Results show that sCD40L was raised in IC at median 68 (IQR 28–333) pg/ml and in CLI at 64 (34–282) pg/mL compared to 35 (IQR 28–55) pg/ml in the healthy controls (p=0.009). Levels were no different between IC and CLI. The same distribution pattern was present for soluble P selectin, %platelets CD62+ve and CD63+ve. sCD40L failed to correlate significantly with ABPI (p=0.264), unlike %platelets CD62+ve (p=0.0032) and CD63+ve (p=0.009). Pre-angioplasty sCD40L level of 72 (35–610) ng/ml rose to 100 ng/ml (IQR=60–237)(p=0.018) post–angioplasty. Plasma sCD40L, in addition to other platelet indices, is raised in peripheral atherosclerosis and is increased by peripheral artery angioplasty, although levels seem unrelated to clinical severity. Failure to correlate with other markers suggest the platelet may not be the sole source of sCD40L, and that other cells may contribute to plasma levels.

Keywords

Platelets - CD40L - peripheral vascular disease - angioplasty - thrombosis - CD154

• References

• 1 Grewal IS, Flavell RA. CD40 and CD154 in cellmediated immunity. Annu Rev Immunol 1998; 16: 111-35.
• 2 Schonbeck U, Libby P. CD40 signalling and plaque instability. Circ Res 2001; 89: 1092-103.
• 3 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
• 4 Deschanet J, Grosset C, Taupin JL. et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 1997; 159: 5640-7.
• 5 Slupsky JR, Kalbas M, Willuweit A. et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80: 1008-14.
• 6 Zhou L, Stordeur P, de Lavareille A. et al. CD40 engagement on endothelial cells promotes tissue factordependent procoagulant activity. Thromb Haemost 1998; 79: 1025-8.
• 7 Andre P, Prasad KS, Denis CV. et al. CD40L stabilises arterial thrombi by a beta 3 integrin-dependent mechanism. Nat Med 2002; 8: 247-52.
• 8 Prasad KS, Andre P, He M. et al. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 2003; 100: 12367-71.
• 9 Blann AD, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation?. Atherosclerosis 1997; 128: 135-8.
• 10 Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-79.
• 11 Marx N, Imhof A, Froehlich J. et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type-2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-7.
• 12 Varo N, Vicent D, Libby P. et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. A novel target of thiazolidinediones. Circulation 2003; 107: 2664-9.
• 13 Damas JK, Otterdal K, Yndestad A. et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 2004; 110: 999-1005.
• 14 Aukrust P, Muller F, Ueland T. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-20.
• 15 Cipollone F, Ferri C, Desideri G. et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003; 108: 2776-82.
• 16 Schmitz G, Rothe G, Ruf A. et al. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 886-96.
• 17 Lim HS, Blann AD, Lip GYH. Soluble CD40L, soluble P selectin, interleukin-6 and tissue factor in diabetes. Circulation 2004; 109: 2524-8.
• 18 Heeschen C, Dimmeler S, Hamm CW. et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-11.
• 19 Schonbeck U, Varo N, Libby P. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-8.
• 20 Varo N, de Lemos JA, Libby P. et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049-52.
• 21 Stumpf C, Lehner C, Eskafi S. et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003; 5: 629-37.
• 22 Anand SX, Viles-Gonzalez JF, Badimon JJ. et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90: 377-84.
• 23 Otterdal K, Pedersen TM, Solum NO. Release of soluble CD40 ligand after platelet activation; Studies on the solubilization phase. Thromb Res 2004; 114: 167-77.
• 24 Ahn ER, Lander G, Jy W. et al. Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk. Thromb Res 2004; 114: 143-8.
• 25 Furman I M, Krueger LA, Linden MD. et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004; 43: 2319-25.
• 26 Cipollone F, Mezzetti A, Porreca E. et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399-402.
• 27 Tsiara S, Elisaf M, Jagroop IA. et al. Platelets as predictors of vascular risk: is there a practical index of platelet activity?. Clin Appl Thromb Hemost 2003; 9: 177-90
• 28 Weber AA, Hermann AA, Rauch BH. et al. Molecular identity of platelet CD40 ligand (CD40L). Thromb Haemost 2001; 86: 718
• 29 Hermann A, Rauch BH, Braun M. et al. Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
• 30 Henn V, Steinbach S, Buchner K. et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-54.
• 31 Blake GJ, Ostfeld RJ, Yucel EK et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high resolution MRI. Arteriocler Thromb Vasc Biol 2003; 23: e11-e14.
• 32 Amirkhosravi A, Amaya M, Desai H. et al. Platelet- CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. Blood Coagul Fibrinolysis 2002; 13: 505-12.
• 33 Kinlay S, Schwartz GG, Olsson AG. et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004; 110: 386-91.
• 34 Malyszko J, Malyszko JS, Hryszko T. et al. Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Blood Coagul Fibrinolysis 2004; 15: 463-7.
• 35 Reul RM, Fang JC, Denton MD. et al. CD40 and CD40 ligand are co-expressed on microvessels in vivo in human allograft rejection. Transplantation 1997; 64: 1765-74.